Perampanel (Fycompa): First-in-Class AMPA Receptor Antagonist for Epilepsy
Perampanel (brand name Fycompa) is the first antiepileptic drug to be approved that acts specifically through non-competitive antagonism of AMPA-type glutamate receptors. This represents a genuinely novel mechanism of action that distinguishes perampanel from all previously available antiepileptic drugs, which act through various other mechanisms including sodium channel blockade, calcium channel modulation, GABA enhancement, or potassium channel opening. By targeting the excitatory glutamate system rather than the inhibitory GABA system or ion channels, perampanel provides an important new therapeutic approach for drug-resistant epilepsy.
Perampanel is approved as adjunctive (add-on) therapy for focal (partial-onset) seizures with or without secondary generalization, and for primary generalized tonic-clonic seizures (PGTCS), in patients aged 4 years and above. It is not approved as monotherapy for epilepsy. Its once-daily bedtime dosing schedule, driven by a long half-life of approximately 105 hours, provides convenience for patients but also means that drug levels build up slowly during titration and persist for extended periods after discontinuation. A distinctive feature of perampanel's clinical profile is its psychiatric side effect burden, including irritability, aggression, and hostility, which has led to an FDA black box warning for serious psychiatric and behavioral adverse reactions.
Mechanism of Action
Glutamate is the principal excitatory neurotransmitter in the mammalian CNS. AMPA receptors (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors) are ionotropic glutamate receptors mediating the fast excitatory synaptic transmission that underlies most neuronal communication. They are tetrameric ion channels composed of GluA1-4 subunits, which upon activation by glutamate allow rapid influx of sodium (and in some configurations, calcium) ions, depolarizing the postsynaptic membrane and propagating excitatory signals. In epilepsy, excessive and synchronized glutamatergic excitation is a fundamental driver of seizure generation and propagation. Perampanel is a highly selective, non-competitive antagonist of AMPA receptors: it binds to a site on the AMPA receptor distinct from the glutamate binding site, producing a conformational change that prevents the receptor from opening in response to glutamate binding, regardless of glutamate concentration. This non-competitive (allosteric) antagonism means that perampanel's inhibitory effect cannot be overcome by high glutamate concentrations during seizure activity, which is a theoretical advantage over competitive antagonists. By reducing AMPA receptor-mediated excitatory neurotransmission, perampanel decreases neuronal hyperexcitability and the likelihood of synchronous discharge required for seizure generation. The drug has a very long half-life (approximately 105 hours) due to high lipophilicity and extensive protein binding, supporting once-daily dosing. It is metabolized primarily by CYP3A4 with some contribution from CYP3A5 and CYP1A2.
Indications
Perampanel is indicated as adjunctive therapy in patients aged 4 years and above with epilepsy. It is approved for two seizure types. First, for focal seizures (partial-onset seizures) with or without secondary generalization, in patients who are not adequately controlled on their existing antiepileptic drug regimen. Focal seizures arise from a localized area of the brain and may remain focal or spread to cause generalized convulsions (secondary generalization). Perampanel reduces the frequency of focal seizures when added to existing treatment, as demonstrated in phase 3 clinical trials (Study 304, 305, and 306) which collectively showed statistically significant reductions in focal seizure frequency. Second, for primary generalized tonic-clonic seizures (PGTCS), perampanel is indicated as adjunctive therapy in patients with generalized epilepsy syndromes (such as juvenile myoclonic epilepsy) who experience PGTCS not adequately controlled by existing therapy. The extension of indication to PGTCS was based on the STUDY 332 trial which demonstrated significant reduction in PGTCS frequency. Perampanel does not have an approved indication for absence seizures or myoclonic seizures as monotherapy. Its use in combination with valproate or other broad-spectrum antiepileptics for juvenile myoclonic epilepsy is clinically common given the generalized seizure indication.
Dosage and Administration
Perampanel is taken once daily at bedtime, which utilizes its long half-life to maintain stable plasma concentrations throughout the day while concentrating the peak concentration and associated CNS side effects (dizziness, sedation) during sleep. Perampanel is available as film-coated tablets (2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg) and as an oral suspension (0.5 mg/mL) for patients who have difficulty swallowing tablets. For adults and adolescents (12 years and above) not taking enzyme-inducing antiepileptic drugs (EIAEDs), the recommended starting dose is 2 mg once daily at bedtime, titrated by 2 mg increments at weekly or fortnightly intervals as tolerated, to an effective dose typically between 4 and 12 mg per day. For patients on concomitant EIAEDs (which substantially reduce perampanel exposure through CYP3A4 induction), the starting dose remains 2 mg but more rapid titration to higher doses may be needed, with a maximum dose of 12 mg per day. For pediatric patients aged 4 to 11 years, weight-based dosing applies. Dose titration should be conducted slowly to minimize CNS adverse effects. If perampanel is stopped, gradual tapering over at least one week is recommended to reduce the risk of seizure recurrence.
Side Effects
Dizziness is the most common adverse effect of perampanel and is dose-dependent, occurring in a significant proportion of patients at higher doses. Taking perampanel at bedtime reduces the functional impact of dizziness. Somnolence and fatigue are also frequently reported and are similarly managed by bedtime dosing. Balance disorders, including unsteady gait and ataxia, particularly at higher doses, can be limiting, especially in older patients. Weight gain has been reported in clinical trials and can be clinically significant with long-term therapy. The most serious and distinctive adverse effects of perampanel are neuropsychiatric in nature. Irritability, hostility, aggression, and anger are reported in a meaningful proportion of patients and can be severe, leading to treatment discontinuation in some cases. Homicidal ideation and threatening behavior have been reported rarely. Physical aggression toward others has also been documented. These psychiatric adverse effects occur more commonly at higher doses and in patients with a pre-existing psychiatric history. The FDA has issued a black box warning for serious psychiatric and behavioral adverse reactions with perampanel. Additionally, perampanel may cause mood disorders including anxiety and depression. Euphoria and abuse potential have been reported, leading to its classification as a Schedule III controlled substance in the USA, though scheduling varies by country. Falls, particularly related to dizziness and ataxia, are a practical concern.
Interactions
Perampanel is metabolized primarily by CYP3A4 (with lesser contributions from CYP3A5 and CYP1A2). This creates clinically significant interactions with enzyme-inducing antiepileptic drugs (EIAEDs), which are strong CYP3A4 inducers. Carbamazepine, oxcarbazepine, phenytoin, phenobarbital, and primidone all substantially reduce perampanel plasma concentrations (by approximately 50 to 67 percent) through CYP3A4 induction, necessitating higher perampanel doses to achieve therapeutic effect and requiring dose adjustment when these drugs are added, removed, or changed in dose. Topiramate at higher doses has also been shown to moderately induce CYP3A4 and reduce perampanel concentrations. Rifampicin and other strong non-antiepileptic CYP3A4 inducers will similarly reduce perampanel levels. Non-inducing antiepileptic drugs such as valproate, lamotrigine, levetiracetam, and lacosamide do not significantly affect perampanel pharmacokinetics. Perampanel itself has modest pharmacokinetic effects on some co-administered antiepileptic drugs; it may modestly reduce lamotrigine plasma levels and has been reported to affect the pharmacokinetics of oral contraceptives (particularly levonorgestrel), potentially reducing contraceptive efficacy at higher perampanel doses (12 mg per day). Women of childbearing potential taking perampanel at 12 mg per day should use non-hormonal contraception or discuss alternative contraceptive methods with their physician. CNS depressants including alcohol significantly potentiate the CNS effects of perampanel, particularly sedation and behavioral effects; patients are strongly advised to avoid alcohol during perampanel treatment.
Special Notes
The psychiatric side effects of perampanel require careful patient selection and close monitoring throughout treatment. Patients with a history of psychiatric disorders including psychosis, bipolar disorder, or significant aggression represent a population where the risk-benefit balance must be carefully considered. Pre-treatment psychiatric assessment is recommended, and patients and families or caregivers should receive explicit counseling about the risk of behavioral changes including irritability, aggression, and hostility. They should be instructed to report behavioral changes promptly. In patients who develop significant psychiatric adverse effects, dose reduction or discontinuation should be considered. The FDA black box warning for serious psychiatric and behavioral adverse reactions is a mandatory disclosure element in US prescribing and patient communication. Perampanel's once-daily bedtime dosing is a significant practical advantage for adherence. Given its long half-life, steady-state is reached after approximately two to three weeks of regular dosing, and concentration changes after dose adjustments take time to stabilize. Regular assessment of seizure control, adverse effects, and drug interactions with co-administered antiepileptic drugs is essential. In women of childbearing age, the potential interaction with hormonal contraceptives at the 12 mg dose requires explicit discussion and contraceptive planning. Perampanel has been assigned to pregnancy category C; available data on human pregnancy exposure are limited and physicians should counsel patients accordingly.
Related Topics
Frequently Asked Questions
What makes perampanel unique compared to other antiepileptic drugs?
Perampanel is the first and currently only antiepileptic drug that acts through selective non-competitive antagonism of AMPA-type ionotropic glutamate receptors. All other approved antiepileptic drugs work through different mechanisms: sodium channel blockers (carbamazepine, lamotrigine, phenytoin), GABA enhancers (benzodiazepines, phenobarbital, vigabatrin), calcium channel modulators (gabapentin, pregabalin, ethosuximide), SV2A protein modulators (levetiracetam), or potassium channel openers (retigabine). By targeting the primary excitatory neurotransmission pathway through AMPA receptor blockade, perampanel provides a mechanistically complementary approach that may achieve seizure control in patients who have not responded to drugs working through other mechanisms. The non-competitive (allosteric) nature of its AMPA receptor antagonism means that its inhibitory effect cannot be overcome by high glutamate concentrations during seizure activity.
Why is perampanel taken at bedtime rather than in the morning?
Perampanel has a very long plasma half-life of approximately 105 hours, enabling once-daily dosing. Despite the long half-life, there is still a pharmacokinetic peak concentration occurring a few hours after each dose. The most clinically relevant adverse effects of perampanel, particularly dizziness, somnolence, and ataxia, correlate with the peak drug concentration. By taking perampanel at bedtime, the peak concentration occurs during sleep, when CNS effects (dizziness, sedation) are inconsequential for daily functioning and safety. This timing strategy substantially improves patient tolerability and treatment adherence without compromising the around-the-clock seizure protection provided by the stable trough concentrations maintained by the drug's long half-life. Patients should be advised that even with bedtime dosing, residual sedation and dizziness may be present in the morning, particularly during dose titration phases, and caution is needed regarding driving and operating machinery.
How should behavioral changes during perampanel therapy be managed?
Behavioral changes including irritability, hostility, anger, and aggression are among the most important adverse effects to monitor during perampanel treatment. If a patient or their family or caregivers report personality changes, increased anger, irritability toward others, or threatening behavior, these symptoms should be promptly assessed by the treating neurologist or epileptologist. Mild irritability may be managed by reducing the perampanel dose by one step (2 mg), which often reduces behavioral symptoms while maintaining seizure control. More severe behavioral changes, including aggression or threatening behavior, typically require more substantial dose reduction or complete discontinuation of perampanel, with appropriate safety management for the patient and those around them. Psychiatric consultation may be appropriate. Patients should be assessed for pre-existing psychiatric vulnerabilities before starting perampanel, and the black box warning content should be communicated clearly to patients, families, and caregivers at treatment initiation in clear, accessible language.
Sources
- Hanada T et al. Perampanel: A selective, noncompetitive AMPA receptor antagonist with activity in models of epilepsy and neuropathic pain. J Pharmacol Exp Ther. 2011.
- French JA et al. Adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012.
- EMA: Fycompa (perampanel) Summary of Product Characteristics, current version.